Neogen (NEOG) vs Alpha Teknova (TKNO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neogen (NEOG) has outperformed Alpha Teknova (TKNO) over the past year, gaining 101.2% versus a gain of 58.9%. Over five years, TKNO leads with a -63.5% price change compared with -71.5% for NEOG. Neogen is the larger company by market cap ($2.56 billion vs $453.1 million), about 5.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NEOG | TKNO |
|---|---|---|
| Share price | $11.71 | $8.44 |
| Market cap | $2.56B | $453.13M |
| 1-day change | +0.26% | -3.10% |
| YTD return | +67.53% | +122.11% |
| 1-year return | +101.20% | +58.95% |
| 5-year return | -71.47% | -63.46% |
| Forward P/E | 30.82 | — |
| EPS (TTM) | $-0.26 | $-0.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $870.40M | — |
| Revenue growth (YoY) | -2.72% | — |
| Net income (latest FY) | $-7.90M | — |
| Gross margin | 46.93% | — |
| Operating margin | -2.48% | — |
| Net margin | -0.91% | — |
| 52-week high | $14.26 | $9.48 |
| 52-week low | $5.37 | $1.91 |
| Distance from 52-week high | -17.88% | -10.97% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +19.56% | +6.64% |
| Average volume | 3.14M | 232.69K |
| Shares outstanding | 218.31M | 53.69M |
| Employees | 2,636 | 158 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Neogen is about 5.6 times larger than Alpha Teknova by market value ($2.56B vs $453.13M).
- NEOG has outperformed TKNO by 42.3 percentage points over the past year.
About Neogen
NEOG stock →Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,636 employees
About Alpha Teknova
TKNO stock →Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 158 employees
NEOG vs TKNO FAQ
Which is bigger, Neogen or Alpha Teknova?
Neogen (NEOG) is larger, with a market capitalization of $2.56B compared with $453.13M for Alpha Teknova (TKNO).
Which stock has performed better over the past year, NEOG or TKNO?
NEOG returned +101.20% over the past 12 months, compared with +58.95% for TKNO (price return, excluding dividends). Past performance does not predict future results.
Are Neogen and Alpha Teknova in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.